Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tipifarnib in Advanced Squamous Non-small Cell Lung Cancer With HRAS Mutations
NCT03496766Phase 2Terminated
- Sponsor
- Fundación GECP
- Start
- May 2018
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tipifarnib in squamous cell carcinoma of the lung (SCCL), sponsored by Fundación GECP. Primary endpoint: Overall Response Rate at 6 weeks. Started May 2018; status: terminated.
02
Drugs
tipifarnib
03
Conditions
squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT03496766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03496766.